Results for tag: "Poractant Alfa"

Poractant Alfa is a synthetic surfactant used in the treatment of Respiratory Distress Syndrome (RDS) in premature infants. It is a natural surfactant replacement therapy that helps to reduce the risk of mortality and morbidity associated with RDS. It is administered through an endotracheal tube and works by reducing surface tension in the lungs, allowing for improved oxygenation and ventilation. Poractant Alfa is the only approved synthetic surfactant in the United States and is used in over 80 countries worldwide. The Poractant Alfa market is a rapidly growing segment of the respiratory drugs market. It is expected to witness a steady growth rate over the forecast period due to the increasing prevalence of RDS in premature infants and the growing awareness of the benefits of surfactant replacement therapy. Some of the major companies in the Poractant Alfa market include Chiesi Farmaceutici, Baxter International, Mallinckrodt Pharmaceuticals, and Grifols. Show Less Read more